

OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/912,414

DATE: 11/26/2001

TIME: 12:36:43

Input Set : A:\620-151.app

Output Set: N:\CRF3\11212001\I912414.raw

ENTERED

4 <110> APPLICANT: Muller, Rolf
5 Kontermann, Roland E
6 Montigiani, Silvia
8 <120> TITLE OF INVENTION: Transcription factor E2F DNA-binding domain inhibitor
9 peptides and their use
11 <130> FILE REFERENCE: 620-151
13 <140> CURRENT APPLICATION NUMBER: US 09/912,414
14 <141> CURRENT FILING DATE: 2001-07-26
16 <150> PRIOR APPLICATION NUMBER: PCT/GB00/00227
17 <151> PRIOR FILING DATE: 2000-01-26
19 <150> PRIOR APPLICATION NUMBER: GB 9901710.5
20 <151> PRIOR FILING DATE: 1999-01-26
22 <160> NUMBER OF SEQ ID NOS: 40
24 <170> SOFTWARE: PatentIn Ver. 2.1
26 <210> SEQ ID NO: 1
27 <211> LENGTH: 6
28 <212> TYPE: PRT
29 <213> ORGANISM: Artificial Sequence
31 <220> FEATURE:
32 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
33 peptide
35 <400> SEQUENCE: 1
36 Phe Trp Leu Arg Phe Thr
37 1 5
41 <210> SEQ ID NO: 2
42 <211> LENGTH: 6
43 <212> TYPE: PRT
44 <213> ORGANISM: Artificial Sequence
46 <220> FEATURE:
47 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
48 peptide
50 <400> SEQUENCE: 2
51 Trp Val Arg Trp His Phe
52 1 5
56 <210> SEQ ID NO: 3
57 <211> LENGTH: 6
58 <212> TYPE: PRT
59 <213> ORGANISM: Artificial Sequence
61 <220> FEATURE:
62 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
63 peptide
65 <400> SEQUENCE: 3
66 Trp His Phe Ile Phe Trp
67 1 5
71 <210> SEQ ID NO: 4
72 <211> LENGTH: 15
73 <212> TYPE: PRT

RAW SEQUENCE LISTING

DATE: 11/26/2001

PATENT APPLICATION: US/09/912,414

TIME: 12:36:43

Input Set : A:\620-151.app

Output Set: N:\CRF3\11212001\I912414.raw

74 <213> ORGANISM: Artificial Sequence
 76 <220> FEATURE:
 77 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 78 peptide
 80 <400> SEQUENCE: 4
 81 Ile Trp Leu Ser Gly Leu Ser Arg Gly Val Trp Val Ser Phe Pro
 82 1 5 10 15
 86 <210> SEQ ID NO: 5
 87 <211> LENGTH: 15
 88 <212> TYPE: PRT
 89 <213> ORGANISM: Artificial Sequence
 91 <220> FEATURE:
 92 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 93 peptide
 95 <400> SEQUENCE: 5
 96 Gly Ser Arg Ile Leu Thr Phe Arg Ser Gly Ser Trp Tyr Ala Ser
 97 1 5 10 15
 101 <210> SEQ ID NO: 6
 102 <211> LENGTH: 16
 103 <212> TYPE: PRT
 104 <213> ORGANISM: Drosophila melanogaster
 106 <400> SEQUENCE: 6
 107 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
 108 1 5 10 15
 112 <210> SEQ ID NO: 7
 113 <211> LENGTH: 5
 114 <212> TYPE: PRT
 115 <213> ORGANISM: Artificial Sequence
 117 <220> FEATURE:
 118 <221> NAME/KEY: SITE
 119 <222> LOCATION: (1)
 120 <223> OTHER INFORMATION: In Claims 1 & 2, Xaa is an amino terminal or a sequence of
 from 1
 121 to 4 amino acids
 123 <220> FEATURE:
 124 <221> NAME/KEY: SITE
 125 <222> LOCATION: (1)
 126 <223> OTHER INFORMATION: In Claim 3, Xaa is an amino terminal or a sequence of from 1
 127 to 4 amino acids each of which are selected from Gly, Ala, Ile, Leu,
 128 Val, Ser, Thr, Lys, or Arg
 130 <220> FEATURE:
 131 <221> NAME/KEY: SITE
 132 <222> LOCATION: (2)
 133 <223> OTHER INFORMATION: In Claim 1, Xaa is an aromatic amino acid
 135 <220> FEATURE:
 136 <221> NAME/KEY: SITE
 137 <222> LOCATION: (2)
 138 <223> OTHER INFORMATION: In Claims 2 and 3, Xaa is Phe or Trp
 140 <220> FEATURE:
 141 <221> NAME/KEY: SITE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/912,414

DATE: 11/26/2001

TIME: 12:36:43

Input Set : A:\620-151.app

Output Set: N:\CRF3\11212001\I912414.raw

142 <222> LOCATION: (3)
 143 <223> OTHER INFORMATION: In Claims 1 & 2, Xaa is from two to four amino acids
 145 <220> FEATURE:
 146 <221> NAME/KEY: SITE
 147 <222> LOCATION: (3)
 148 <223> OTHER INFORMATION: In Claim 3, Xaa is from two to four amino acids each of
 which are
 149 selected from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His or Phe
 151 <220> FEATURE:
 152 <221> NAME/KEY: SITE
 153 <222> LOCATION: (4)
 154 <223> OTHER INFORMATION: In Claim 1, Xaa is an aromatic amino acid
 156 <220> FEATURE:
 157 <221> NAME/KEY: SITE
 158 <222> LOCATION: (4)
 159 <223> OTHER INFORMATION: In Claim 2, Xaa is Phe or Trp
 161 <220> FEATURE:
 162 <221> NAME/KEY: SITE
 163 <222> LOCATION: (4)
 164 <223> OTHER INFORMATION: In Claim 3, Xaa is Trp
 167 <220> FEATURE:
 168 <221> NAME/KEY: SITE
 169 <222> LOCATION: (5)
 170 <223> OTHER INFORMATION: In Claims 1 & 2, Xaa is a carboxy terminal or a sequence of
 from
 171 one to four amino acids
 173 <220> FEATURE:
 174 <221> NAME/KEY: SITE
 175 <222> LOCATION: (5)
 176 <223> OTHER INFORMATION: In Claim 3, Xaa is a carboxy terminal or a sequence of from
 177 one to four amino acids each of which are selected from Gly, Ala, Ile,
 178 Leu, Val, Ser, Thr, Lys, Arg, His, Phe or Tyr
 181 <220> FEATURE:
 182 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 183 peptide
 185 <400> SEQUENCE: 7
 W--> 186 Xaa Xaa Xaa Xaa Xaa
 187 1 5
 191 <210> SEQ ID NO: 8
 192 <211> LENGTH: 6
 193 <212> TYPE: PRT
 194 <213> ORGANISM: Artificial Sequence
 196 <220> FEATURE:
 197 <221> NAME/KEY: SITE
 198 <222> LOCATION: (2)..(3), (5)..(6)
 199 <223> OTHER INFORMATION: Each Xaa is independently any amino acid
 201 <220> FEATURE:
 202 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 203 peptide
 205 <400> SEQUENCE: 8
 W--> 206 Trp Xaa Xaa Trp Xaa Xaa

RAW SEQUENCE LISTING

DATE: 11/26/2001

PATENT APPLICATION: US/09/912,414

TIME: 12:36:43

Input Set : A:\620-151.app

Output Set: N:\CRF3\11212001\I912414.raw

```

207      1      5
211 <210> SEQ ID NO: 9
212 <211> LENGTH: 6
213 <212> TYPE: PRT
214 <213> ORGANISM: Artificial Sequence
216 <220> FEATURE:
217 <221> NAME/KEY: SITE
218 <222> LOCATION: (2)..(3), (5)
219 <223> OTHER INFORMATION: Each Xaa is independently any amino acid selected
220      from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
221      His, or Phe
223 <220> FEATURE:
224 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
225      peptide
227 <400> SEQUENCE: 9
W--> 228 Trp Xaa Xaa Trp Xaa Phe
229      1      5
233 <210> SEQ ID NO: 10
234 <211> LENGTH: 9
235 <212> TYPE: PRT
236 <213> ORGANISM: Artificial Sequence
238 <220> FEATURE:
239 <221> NAME/KEY: SITE
240 <222> LOCATION: (2)..(3), (5), (7)..(8)
241 <223> OTHER INFORMATION: Each Xaa is independently any amino acid selected
242      from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
243      His, or Phe
245 <220> FEATURE:
246 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
247      peptide
249 <400> SEQUENCE: 10
W--> 250 Trp Xaa Xaa Trp Xaa Phe Xaa Xaa Trp
251      1      5
255 <210> SEQ ID NO: 11
256 <211> LENGTH: 6
257 <212> TYPE: PRT
258 <213> ORGANISM: Artificial Sequence
260 <220> FEATURE:
261 <221> NAME/KEY: SITE
262 <222> LOCATION: (2)..(3)
263 <223> OTHER INFORMATION: Each Xaa is independently any amino acid selected
264      from Gly, Ala, Ile, Leu, Val, Ser, Thr, or Arg
266 <220> FEATURE:
267 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
268      peptide
270 <400> SEQUENCE: 11
W--> 271 Trp Xaa Xaa Trp His Phe
272      1      5
276 <210> SEQ ID NO: 12

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/912,414

DATE: 11/26/2001

TIME: 12:36:43

Input Set : A:\620-151.app

Output Set: N:\CRF3\11212001\I912414.raw

```

277 <211> LENGTH: 8
278 <212> TYPE: PRT
279 <213> ORGANISM: Artificial Sequence
281 <220> FEATURE:
282 <221> NAME/KEY: SITE
283 <222> LOCATION: (1)..(2), (4)..(7)
284 <223> OTHER INFORMATION: Each Xaa is independently any amino acid
286 <220> FEATURE:
287 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
288     peptide
290 <400> SEQUENCE: 12
W--> 291 Xaa Xaa Phe Xaa Xaa Xaa Xaa Trp
292     1           5
296 <210> SEQ ID NO: 13
297 <211> LENGTH: 8
298 <212> TYPE: PRT
299 <213> ORGANISM: Artificial Sequence
301 <220> FEATURE:
302 <221> NAME/KEY: SITE
303 <222> LOCATION: (1)..(2), (4)..(7)
304 <223> OTHER INFORMATION: Each Xaa is independently any amino acid selected
305     from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
306     His, Phe, or Tyr
308 <220> FEATURE:
309 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
310     peptide
312 <400> SEQUENCE: 13
W--> 313 Xaa Xaa Phe Xaa Xaa Xaa Xaa Trp
314     1           5
318 <210> SEQ ID NO: 14
319 <211> LENGTH: 8
320 <212> TYPE: PRT
321 <213> ORGANISM: Artificial Sequence
323 <220> FEATURE:
324 <221> NAME/KEY: SITE
325 <222> LOCATION: (1)..(2)
326 <223> OTHER INFORMATION: Each Xaa is independently any amino acid selected
327     from Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg,
328     His, Phe, or Tyr
330 <220> FEATURE:
331 <221> NAME/KEY: SITE
332 <222> LOCATION: (5)
333 <223> OTHER INFORMATION: Xaa is independently any amino acid selected from
334     Gly, Ala, Ile, Leu, Val, Ser, Thr, Lys, Arg, His,
335     Phe, or Tyr
337 <220> FEATURE:
338 <221> NAME/KEY: SITE
339 <222> LOCATION: (6)
340 <223> OTHER INFORMATION: Xaa is independently any amino acid selected from

```

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/912,414

DATE: 11/26/2001

TIME: 12:36:44

Input Set : A:\620-151.app

Output Set: N:\CRF3\11212001\I912414.raw

L:186 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:206 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:228 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:250 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:291 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:313 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:356 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:402 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15